Life sciences

A senior life sciences appointment is rarely a routine commercial appointment. The leaders who run these businesses operate in environments shaped by clinical evidence, regulatory pathways, and the scientific discipline of the underlying science. The wrong appointment can set a programme, a product, or a regulatory submission back by months or quarters that the business cannot recover - and the right one can compress those same timelines and open the next round of investment, partnership, or product launch. Reaching the right candidate, almost always already in post at a peer organisation, is the work of a specialist consultant who understands the science, the regulators, and the people running the businesses worth running.

Life Sciences sub-sectors we cover

The life sciences sector is broad, and the leadership profile required varies significantly across its sub-sectors. Stone Executive operates across each of the principal areas of the UK life sciences industry.

Pharmaceuticals. From global pharmaceutical groups through to mid-cap and specialty pharma businesses, we appoint senior leaders across R&D, clinical development, regulatory affairs, manufacturing, and commercial. See: pharmaceutical executive search.

Biotech and biopharma. Discovery-stage, clinical-stage, and commercial-stage biotech businesses, including listed and venture-backed companies. We work with chief executives, CMOs, CSOs, and senior R&D leaders to support pipeline progression and commercial readiness. See: biotech executive search.

Medical devices. From global medtech corporations through to specialist device businesses, we appoint senior leaders in product development, regulatory, quality, manufacturing, and commercial leadership. See: medical device executive search.

Diagnostics. In vitro diagnostics, molecular diagnostics, point-of-care, and laboratory services businesses, where the leadership requires a combination of clinical, regulatory, and commercial judgement. Diagnostics executive search at this level turns on assay and platform credibility as much as on commercial record, and on leaders who can hold a serious conversation with a laboratory director and an NHS procurement lead in the same week.

Contract research and contract manufacturing (CRO / CDMO). The service organisations supporting the wider life sciences sector - including clinical research organisations, contract development and manufacturing organisations, and specialist service providers.

Digital health and healthtech. Software, data, and technology businesses serving life sciences and healthcare - see: healthtech executive search.

Animal health, consumer health, and adjacent markets. Including veterinary pharmaceuticals, consumer-facing health businesses, and the broader healthcare market - see: healthcare executive search.

The UK Life Sciences clusters we work across

The UK life sciences industry is concentrated in a small number of clusters, and where a business sits shapes who it can realistically appoint. The Golden Triangle of London, Oxford, and Cambridge, the Cambridge Biomedical Campus, the Stevenage cell and gene therapy cluster, and Alderley Park in Cheshire each hold a distinct senior leadership community.

The Golden Triangle. London, Oxford, and Cambridge hold the densest concentration of research universities, teaching hospitals, venture investors, and university spin-outs in the country, and the senior life sciences community concentrates with them. For a business inside the triangle, the practical candidate pool is larger than the national market suggests. For a business outside it, a senior appointment usually means either persuading a leader to relocate or structuring the role so the science stays where it is and the leadership travels. We take a view on which is realistic at briefing.

Cambridge Biomedical Campus. The campus brings Addenbrooke’s Hospital, the Royal Papworth, the MRC Laboratory of Molecular Biology, the Cancer Research UK Cambridge Institute, and AstraZeneca’s research centre onto one site, and the leadership profiles it produces are unusually translational: individuals who have worked across clinical practice, discovery science, and commercial development. Those are the candidates worth reaching for a clinical-stage biotech chief medical officer or chief scientific officer, and they are almost never visibly available.

Stevenage and the cell and gene therapy cluster. Stevenage has become the centre of UK cell and gene therapy, built around the Cell and Gene Therapy Catapult manufacturing centre, the Stevenage Bioscience Catalyst incubator, and the GSK site alongside them. The leadership requirement there is specific: heads of manufacturing and technical operations who understand autologous and allogeneic processes, quality leaders who have taken an advanced therapy through inspection, and chief executives who can hold a scientific board and an investor syndicate at the same time.

Alderley Park and the North West corridor. Alderley Park in Cheshire, the former AstraZeneca research site now operated as a bioscience campus, anchors a corridor running through Manchester and out towards Liverpool, and it is where a large number of smaller UK life sciences organisations make their first senior commercial appointment. That appointment carries more weight than its title suggests, because the person who takes it sets the standard for everyone appointed after them.

Cluster geography is not a footnote on a life sciences executive search. It sets the realistic candidate pool, the relocation conversation, and whether a hybrid arrangement is credible for a role that has to sit near a laboratory or a manufacturing suite. We map the relevant cluster and its neighbours at the start of every engagement, and we say plainly where the market is thin.

Senior Life Sciences roles we recruit

Stone Executive’s life sciences practice handles appointments across the full spectrum of senior leadership.

• Chief Executive Officer for pharmaceutical, biotech, medical device, diagnostics, and CRO/CDMO businesses
• Chief Medical Officer (CMO) and Chief Scientific Officer (CSO)
• Chief Operating Officer and Chief Financial Officer of life sciences businesses
• Head of Regulatory Affairs and Vice President of Regulatory
• Head of Clinical Operations and Vice President of Clinical Development
• Head of R&D and Vice President of Discovery
• Chief Commercial Officer and General Manager (UK / Europe / international)
• Head of Manufacturing and Head of Quality
• Head of Market Access, Pricing, and Reimbursement
• Chair, Non-Executive Director, and senior advisory appointments to life sciences boards - supported by our board-level practice

Each is assessed differently, and the sections below set out what a life science executive search actually tests in the roles we are briefed on most often.

Clinical, scientific, and development leadership

The Chief Medical Officer is the appointment that most often decides whether a clinical-stage organisation is credible to a regulator, an investor, and a partner, and the search tests medical standing, trial design judgement, and the ability to carry a scientific argument in a commercial room. The Chief Scientific Officer is assessed on discovery track record, platform judgement, and the willingness to close a programme that is not working. The Chief Development Officer, where that role sits separately, owns the path from candidate molecule or device through to filing, and is assessed on programmes actually delivered rather than portfolios inherited.

Regulatory, quality, and technical operations

The Head of Regulatory Affairs shapes the submission strategy that sets the market entry date, and the search separates a small molecule regulatory leader from a device or diagnostics one, because the pathways and the evidence requirements are not interchangeable. The Qualified Person is a named, legally accountable role under UK and EU medicines legislation: a QP certifies each batch for release, is personally answerable for that certification, and cannot be appointed on commercial fit alone. Head of Quality and QA appointments are tested on inspection history and on the judgement to hold a release decision under commercial pressure. Technical Operations leadership covers manufacturing, supply, and MSAT, and at scale-up it often decides whether a launch holds its date.

Medical Affairs, market access, and commercial leadership

Medical Affairs sits between the clinical evidence and the market, and the leaders who do it well are judged on scientific standing with clinicians, not on sales performance. Market Access leadership is assessed on health economics literacy, on NICE and NHS commissioning experience for UK-facing roles, and on payer negotiation across Europe and further afield. Chief Commercial Officer and General Manager appointments in life sciences executive recruitment are tested on launch record, on portfolio judgement, and on whether the individual has operated at the stage the organisation is actually at.

Life Sciences boards

Chair and Non-Executive Director appointments to life sciences boards are a different exercise again. A clinical-stage board needs at least one director who can interrogate the science and one who has taken an organisation through a financing or an exit, and the balance between them is usually where the brief is decided. We appoint chairs, non-executive directors, and senior advisers to life sciences boards, and where the mandate is the chief executive itself we run it through our CEO search practice.

Why specialist Life Sciences search matters

Senior life sciences hiring goes wrong when the search is run on commercial criteria alone. A chief medical officer is not just a senior physician; they are the bridge between the science, the regulator, and the commercial organisation, and the right person needs credibility on all three sides. A head of regulatory affairs is not just a compliance leader; they are the person who shapes the regulatory submission strategy that determines whether a product reaches market on schedule. Generic recruitment, working from a CV-led shortlist, rarely surfaces those distinctions.

Stone Executive’s life sciences consultants work specifically in the senior life sciences community, and the searches we run start with a brief that distinguishes a clinical-stage biotech CMO from a commercial-pharma one, a regulatory leader for a small molecule programme from one for a medical device, a chief executive scaling a pre-revenue biotech from one running a multi-product specialty pharma. That precision in the brief is what produces precision in the shortlist - and at this seniority, in this sector, that is what separates a strong appointment from a costly course correction.

Choosing between life sciences headhunters

Life sciences headhunters differ more than their websites suggest, and a short set of tests separates them. The engagement should be retained and exclusive, not contingent and shared across three firms, because a contingent brief rewards speed over accuracy. Sub-sector depth should be evidenced in your own area, in cell and gene therapy or in vitro diagnostics or specialty pharma, and not in life sciences generally. The consultant who takes the brief should be the consultant who runs the search. Confidentiality should be settled in writing before the search begins: who inside the organisation knows, what is said to the market about the mandate, and which organisations are off limits for its duration. Among life sciences executive search firms the answers vary widely, and they are worth putting before the fee is agreed.

Our Life Sciences executive search process

The life sciences executive search process is a retained, research-led sequence in four stages: brief and market map, discreet approach, assessment and shortlist, and appointment and onboarding. A named consultant leads the engagement from the first conversation through to the start date, supported by our in-house research team, and a typical search runs ten to sixteen weeks from briefing to offer acceptance.

Every Stone Executive life sciences search follows the same disciplined sequence, adapted to the seniority and sub-sector of the role. The timetable below is what we work to on a standard assignment, and it’s published because a client planning a senior appointment deserves a date to plan against. International candidate pools, scientific and regulatory due diligence, and financing-linked timing are what push an engagement towards the longer end of it.

• Weeks 1 to 2: brief and market map
• Weeks 3 to 7: discreet approach and initial assessment
• Weeks 8 to 12: shortlist presentation and client interviews
• Weeks 12 to 16: offer, negotiation, and acceptance

Brief and market map

We work directly with the chair, the chief executive, the investor, or the senior stakeholder responsible for the appointment, to understand the role, the scientific and regulatory context, the commercial position of the business, and the kind of leader who will succeed. For life sciences appointments in particular, the brief has to capture both the science and the commercial reality.

We then identify candidates across the relevant sub-sector and adjacent areas, drawing on Stone Executive’s network of senior life sciences leaders and structured public-domain research. Long lists for senior life sciences roles typically extend internationally, given the cross-border nature of the talent community at this level.

Discreet approach

Senior life sciences leaders are usually in post at a peer organisation and not visibly available. Reaching them well requires the credibility to make a discreet first call land, and the substance to make the conversation worth their time. Every approach is made personally by a consultant, and no candidate is contacted before the proposition has been agreed with the client.

Assessment and shortlist

Assessment is structured, and it produces comparable evidence in place of impressions. Each candidate is interviewed against the criteria agreed at briefing, and referencing begins before the shortlist is presented. We test scientific or technical depth in the relevant modality, regulatory understanding where the role carries it, commercial judgement, and the capacity to operate at the seniority the appointment demands.

We present a shortlist of typically four to six candidates with detailed written profiles covering scientific and commercial track record, motivations, and our independent assessment of fit for the specific role.

Appointment and onboarding

We then manage the formal interview rounds, candidate communication, and any additional due diligence the engagement requires - including for regulated roles or roles requiring international relocation. We advise on the structure and level of the offer, handle the negotiation and any counter-offer, and complete referencing before the appointment is confirmed.

At this seniority a notice period commonly adds a further three to six months before the appointed leader takes up post, and where the role carries a personal regulatory accountability such as a Qualified Person, a formal handover period can extend that further. We stay in contact with both parties throughout.

Track record

Stone Executive has operated as a retained headhunting practice for twenty years, has completed more than 1,000 senior appointments across its sector practices, and was recognised in the Financial Times’ UK’s Leading Recruiters 2024. That record sits behind our Life Sciences practice, which appoints across pharmaceutical, biotech, medical device, diagnostics, and CRO and CDMO organisations.

At Stone Executive we specialise in appointing the exceptional leaders who carry scientific, regulatory, and commercial accountability at the same time, and we combine deep sector knowledge with extensive industry networks and rigorous search methodology. In assessing candidates we go beyond credentials and experience alone, looking for individuals whose capabilities, leadership style, and values align with what the organisation actually needs, because that alignment is what produces appointments that deliver lasting impact and long-term success. Every search is retained and led personally by a named consultant, with our in-house research team behind it.

Recent Life Sciences appointments include clinical and scientific leadership for clinical-stage biotech organisations, commercial and general management leadership for commercial pharmaceutical businesses, regulatory and quality leadership for medical device manufacturers, and senior commercial appointments for diagnostics companies.

FAQs

To discuss a senior life sciences appointment, please contact our team on 0333 800 1560.